Safety and efficacy of transcutaneous vaccination using a patch with the live-attenuated measles vaccine in humans

被引：42

作者：

Etchart, Nathalie

Hennino, Ana

Friede, Martin

Dahel, Karima

Dupouy, Monique

Goujon-Henry, Catherine

Nicolas, Jean-Francois

Kaiserlian, Dominique

机构：

[1] INSERM, U 404, F-69007 Lyon, France

[2] Univ Lyon 1, F-69003 Lyon, France

[3] IFR 128, F-69007 Lyon, France

[4] INSERM, U503, F-69007 Lyon, France

[5] World Hlth Org Initiat Vaccine Res, CH-12211 Geneva, Switzerland

[6] Hosp Civ Lyon, Ctr Hosp Lyon Sud, Serv Immunol Clin Allergol, F-69495 Pierre Benite, France

来源：

VACCINE | 2007年 / 25卷 / 39-40期

关键词：

transcutaneous administration; measles virus; Vaccines; IgA;

D O I：

10.1016/j.vaccine.2007.07.014

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Transcutaneous immunisation (TCI) using a skin patch is a non-invasive vaccination route relevant to mass vaccination against infectious diseases. This phase I/II clinical study, documents that TCI of human adult volunteers with the live-attenuated measles vaccine ROUVAX((R)) is safe and poorly reactogenic. It promotes induction of measles-specific salivary IgA and a tendency to increased frequency of NIV-specific IFN-gamma-producing T cells. However, in contrast to the subcutaneous route, TCI failed to evoke neutralising NIV-specific serum antibodies. Thus, alternative delivery methods and/or devices providing optimal uptake by skin DC should be considered for live-attenuated virus vaccines, such as the measles vaccine. (C) 2007 Elsevier Ltd. All rights reserved.

引用

页码：6891 / 6899

页数：9

共 44 条

[21] Dynamics of measles virus protein expression are reflected in the MHC class I epitope display [J].